Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination
treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around
the world.
Strategic partners to advance global development and commercialization activities:
Taiho has development and commercial rights in Japan and other countries in Asia, excluding China, for domvanalimab, zimberelimab, quemliclustat, etrumadenant and casdatifan. In Japan, Taiho is operationalizing the ongoing Phase 3 PRISM-1 registrational study for quemliclustat and participating in the Phase 3 PEAK-1 registrational study for casdatifan.
Clinical collaborations to explore novel combinations:
Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other
companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global
access to expedite development and commercialization.
Arcus and AstraZeneca have a clinical collaboration on PACIFIC-8, a registrational Phase 3 clinical trial evaluating domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 non-small cell lung cancer, where durvalumab is the standard of care. AstraZeneca is the sponsor of and is operationalizing this study.
Opportunities for collaboration:
CAS
Casdatifan
HIF-2𝛂 Inhibitor
ETRUMA
Etrumadenant
Adenosine A2a/A2b Receptor Antagonist